Skip to main content
Print Save

Generic Lazanda Availability

Last updated on May 11, 2023.

Lazanda is a brand name of fentanyl, approved by the FDA in the following formulation(s):

LAZANDA (fentanyl citrate - spray, metered;nasal)

  • Manufacturer: BTCP PHARMA
    Approval date: June 30, 2011
    Strength(s): EQ 0.1MG BASE (discontinued) [RLD], EQ 0.4MG BASE (discontinued) [RLD]
  • Manufacturer: BTCP PHARMA
    Approval date: December 21, 2015
    Strength(s): EQ 0.3MG BASE (discontinued) [RLD]

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lazanda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method of managing or treating pain
    Patent 8,216,604
    Issued: July 10, 2012
    Inventor(s): Watts; Peter James & Castile; Jonathan David & Lafferty; William Columbus Ian & Smith; Alan
    Assignee(s): Archimedes Development Limited

    A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.

    Patent expiration dates:

    • October 3, 2024
      ✓ 
      Patent use: MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
  • Method of managing or treating pain
    Patent 8,889,176
    Issued: November 18, 2014
    Assignee(s): Depomed, Inc.

    A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.

    Patent expiration dates:

    • January 16, 2024
      ✓ 
      Patent use: MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
  • Intranasal spray device containing pharmaceutical composition
    Patent 9,078,814
    Issued: July 14, 2015
    Assignee(s): DEPOMED, INC.

    An intrasnal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.

    Patent expiration dates:

    • January 8, 2024
      ✓ 
      Drug product
  • Container
    Patent 9,731,869
    Issued: August 15, 2017
    Assignee(s): Archimedes Development Limited

    A container (100), comprising a thread (120) arranged around an opening (110) for engaging a corresponding thread (120) of a closure (400), more than four retention members (140) arranged around the opening (110), each retention member (140) having an end-face for abutting a member (510) on an interior surface of the closure (400) to impede unthreading of the closure (400), the retention members (140) being arranged such that a tangent (170) to each end-face of the retention members (140) intersects a plane (160, 350) bisecting the container (100) at an obtuse angle (171), wherein the retention members (140) are arranged in first and second groups, the first group (141, 410) comprising one retention member (140) having an end-face substantially parallel to the plane bisecting the container (100), and the second group (142, 420) comprising two or more retention members (140), the first and second groups being arranged on one side of the plane (160, 350), each in a respective quadrant of the container (100), the teeth of the second group (142, 420) have a first inter-tooth spacing, and a second inter-tooth spacing is provided between an end-face of the retention member of the first group (141, 410) and a first retention member of the second group (142, 420), and the second inter-tooth spacing is larger than the first inter-tooth spacing.

    Patent expiration dates:

    • January 26, 2032
      ✓ 
      Drug product
  • Patent 9,814,705

    Patent expiration dates:

    • January 8, 2024
      ✓ 
      Drug product

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer